

Alicia F C Okines

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3385931/publications.pdf>

Version: 2024-02-01

39
papers

2,327
citations

361413

20
h-index

345221

36
g-index

39
all docs

39
docs citations

39
times ranked

3825
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 563-571.	2.5	2
2	Abstract OT1-15-01: SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: <i>HER2-mutated breast cancer cohort (ongoing clinical)</i> <i>TJ ETQq0 0 0 rgBTj, Overlock 10 Tf 50 6</i>		
3	Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery. <i>Cancer Research</i> , 2022, 82, P2-01-10-P2-01-10.	0.9	2
4	Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. <i>Clinical Cancer Research</i> , 2022, 28, 1180-1191.	7.0	30
5	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	12.1	24
6	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	9.4	36
7	Abstract PD13-03: Genomic profiling of breast cancer leptomeningeal metastasis (BCLM) reveals a divergent evolution and therapeutic targets. , 2021, , .		0
8	Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience. <i>British Journal of Cancer</i> , 2021, 125, 299-304.	6.4	2
9	Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 361-381.	1.8	8
10	Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1-7.	4.1	3
11	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncologyâ€”Part 1: acute coronary syndromes and acute pericardial diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 947-959.	1.0	37
12	LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM). <i>Neuro-Oncology Advances</i> , 2021, 3, iii11-iii11.	0.7	0
13	Heterogeneous <i>HER2</i> Amplificationâ€”a New Clinical Category of HER2-Positive Breast Cancer?. <i>Cancer Discovery</i> , 2021, 11, 2369-2371.	9.4	5
14	Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 101-111.	2.5	17
15	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 608-622.	7.0	71
16	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
17	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , 2020, 136, 99-106.	2.8	31
18	Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100188.	1.7	13

#	ARTICLE	IF	CITATIONS
19	To Cycle or Fight? CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 21-28.	7.0	46
20	Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience. <i>Breast Journal</i> , 2018, 24, 253-259.	1.0	19
21	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. <i>JAMA Oncology</i> , 2017, 3, 1197.	7.1	398
22	Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience. <i>Breast</i> , 2017, 36, 54-59.	2.2	30
23	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 7543-7549.	7.0	12
24	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2721-2727.	1.6	214
25	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 242-250.	2.8	8
26	Current and Future Therapies for Advanced Gastric Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 239-250.	2.3	28
27	Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. <i>BMC Cancer</i> , 2015, 15, 163.	2.6	25
28	Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 301-318.	3.2	44
29	Targeting the human EGFR family in esophagogastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 492-503.	27.6	132
30	Targeting Angiogenesis in Esophagogastric Adenocarcinoma. <i>Oncologist</i> , 2011, 16, 844-858.	3.7	44
31	Perioperative management of esophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 231-238.	27.6	23
32	Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3945-3950.	1.6	118
33	Trastuzumab in gastric cancer. <i>European Journal of Cancer</i> , 2010, 46, 1949-1959.	2.8	66
34	Metastatic breast cancer presenting as a primary hindgut neuroendocrine tumour. <i>Anticancer Research</i> , 2010, 30, 3015-8.	1.1	1
35	Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal?. <i>European Journal of Cancer</i> , 2009, 45, 2452-2461.	2.8	34
36	Accomplishments in 2008 in the management of localized gastric cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S48-52.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Capecitabine in gastric cancer. <i>Drugs of Today</i> , 2008, 44, 629.	1.1	7
38	An evaluation of FIGO 2000: the first 5 years. <i>Journal of reproductive medicine, The</i> , 2008, 53, 615-22.	0.2	3
39	Capecitabine in advanced gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2851-2861.	1.8	4